mito99Mito-99-0103, Initially developed by Mito BioPharm LLC, Now, its global hhest R&D status is Preclinical, Therapeutic Areas: Endocrinology and Metabolic Disease, Active Indication:Mito-99-0103Mito BioPharm LLC (Mito BioPharm LLC): : 2: Mito